MCID: DCT002
MIFTS: 55

Ductal Carcinoma in Situ

Categories: Cancer diseases

Aliases & Classifications for Ductal Carcinoma in Situ

MalaCards integrated aliases for Ductal Carcinoma in Situ:

Name: Ductal Carcinoma in Situ 12 29 15
Noninfiltrating Intraductal Carcinoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0060074
UMLS 73 C0007124

Summaries for Ductal Carcinoma in Situ

MalaCards based summary : Ductal Carcinoma in Situ, also known as noninfiltrating intraductal carcinoma, is related to comedo carcinoma and breast reconstruction. An important gene associated with Ductal Carcinoma in Situ is AKT1 (AKT Serine/Threonine Kinase 1), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Nolvadex and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and testes, and related phenotypes are Increased cell death HMECs cells and cellular

Wikipedia : 76 Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive... more...

Related Diseases for Ductal Carcinoma in Situ

Diseases related to Ductal Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 245)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 32.6 ERBB2 ESR1
2 breast reconstruction 31.4 BRCA1 BRCA2
3 mammographic density 31.0 CYP19A1 ESR1 PGR
4 gynecomastia 30.7 AR CYP19A1 ESR1 PGR
5 papillary carcinoma 30.3 CDH1 ERBB2 MUC1 PGR
6 bilateral breast cancer 30.1 BRCA1 BRCA2 ERBB2 ESR1 PGR
7 breast disease 30.1 ERBB2 ESR1 KRT5 PGR TP53
8 lobular neoplasia 30.1 BRCA1 CDH1 ERBB2 ESR1 MUC1
9 papilloma 29.4 CCND1 KRT14 KRT5 KRT8 TP53
10 squamous cell carcinoma 27.0 AKT1 CCND1 CDH1 EGFR ERBB2 MUC1
11 breast ductal carcinoma 26.9 AR BRCA1 CCND1 CDH1 EGFR ERBB2
12 breast cancer 21.2 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
13 scirrhous adenocarcinoma 11.0 ERBB2 PGR
14 breast apocrine carcinoma 11.0 ERBB2 PGR
15 endometrium carcinoma in situ 11.0 PGR TP53
16 vulvar syringoma 11.0 ESR1 PGR
17 lung leiomyoma 11.0 ESR1 PGR
18 breast intraductal proliferative lesion 11.0 EGFR ERBB2
19 endometrial clear cell adenocarcinoma 11.0 ESR1 TP53
20 vulvar benign neoplasm 10.9 ESR1 PGR
21 breast papillomatosis 10.9 CCND1 ERBB2
22 trigonitis 10.9 ESR1 PGR
23 brain ependymoma 10.9 EGFR TP53
24 vulvar leiomyoma 10.9 ESR1 PGR
25 glassy cell carcinoma of the cervix 10.9 ERBB2 ESR1 PGR
26 rare adenocarcinoma of the breast 10.9 AKT1 TP53
27 hereditary site-specific ovarian cancer syndrome 10.9 BRCA1 BRCA2
28 vestibular gland benign neoplasm 10.9 ESR1 PGR TP53
29 bartholin's gland adenoma 10.9 ESR1 PGR TP53
30 gallbladder squamous cell carcinoma 10.9 ERBB2 TP53
31 gastric papillary adenocarcinoma 10.9 ERBB2 TP53
32 uterine body mixed cancer 10.9 ERBB2 PGR TP53
33 intracystic papillary adenoma 10.8 EGFR ERBB2 PGR
34 bartholin's gland benign neoplasm 10.8 ESR1 PGR TP53
35 progesterone-receptor negative breast cancer 10.8 EGFR ERBB2 PGR
36 cervical carcinosarcoma 10.8 ESR1 PGR TP53
37 adenosarcoma 10.8 ESR1 PGR TP53
38 non-proliferative fibrocystic change of the breast 10.8 CCND1 ERBB2 TP53
39 oral leukoplakia 10.8 CCND1 ERBB2 TP53
40 papillary serous adenocarcinoma 10.7 BRCA1 PGR TP53
41 tuberculous salpingitis 10.7 BRCA1 BRCA2 ERBB2
42 predominantly cortical thymoma 10.7 ESR1 KRT14 PGR
43 nosophobia 10.7 BRCA1 BRCA2 PGR
44 cancerophobia 10.7 BRCA1 BRCA2 PGR
45 adenomyosis 10.7 ESR1 PGR PTGS2
46 ovarian serous cystadenocarcinoma 10.7 ERBB2 PGR TP53
47 barrett's adenocarcinoma 10.7 ERBB2 PTGS2 TP53
48 salivary gland cancer 10.7 AKT1 EGFR ERBB2
49 uterine corpus cancer 10.7 ERBB2 ESR1 PGR TP53
50 protoplasmic astrocytoma 10.7 PTGS2 TP53

Graphical network of the top 20 diseases related to Ductal Carcinoma in Situ:



Diseases related to Ductal Carcinoma in Situ

Symptoms & Phenotypes for Ductal Carcinoma in Situ

GenomeRNAi Phenotypes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.1 BRCA1 EGFR PGR PIP S100A7 TP53

MGI Mouse Phenotypes related to Ductal Carcinoma in Situ:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 CCND1 BRCA2 CDH1 AR AKT1 BRCA1
2 growth/size/body region MP:0005378 10.48 CCND1 BRCA2 CDH1 AR AKT1 BRCA1
3 digestive/alimentary MP:0005381 10.47 CCND1 BRCA2 CDH1 BRCA1 AR KRT14
4 cardiovascular system MP:0005385 10.46 CCND1 CDH1 AKT1 BRCA1 AR ERBB2
5 endocrine/exocrine gland MP:0005379 10.46 CCND1 BRCA2 CDH1 AKT1 BRCA1 AR
6 homeostasis/metabolism MP:0005376 10.46 BRCA1 CCND1 BRCA2 AR AKT1 ESR1
7 hematopoietic system MP:0005397 10.44 CCND1 BRCA2 AKT1 BRCA1 AR KRT14
8 integument MP:0010771 10.44 CCND1 BRCA2 CDH1 AKT1 BRCA1 AR
9 immune system MP:0005387 10.42 CCND1 BRCA2 CDH1 AR AKT1 BRCA1
10 behavior/neurological MP:0005386 10.4 BRCA1 CCND1 BRCA2 AR AKT1 ESR1
11 mortality/aging MP:0010768 10.4 BRCA1 CCND1 BRCA2 AR AKT1 ESR1
12 embryo MP:0005380 10.37 BRCA2 AR AKT1 BRCA1 ERBB2 ESR1
13 adipose tissue MP:0005375 10.28 BRCA1 AR AKT1 ESR1 KRT14 TP53
14 neoplasm MP:0002006 10.27 CCND1 BRCA2 CDH1 AKT1 BRCA1 AR
15 limbs/digits/tail MP:0005371 10.18 BRCA1 BRCA2 AR ESR1 ERBB2 PGR
16 muscle MP:0005369 10.18 BRCA1 AR AKT1 ESR1 ERBB2 PGR
17 normal MP:0002873 10.18 CCND1 BRCA2 CDH1 AKT1 BRCA1 AR
18 nervous system MP:0003631 10.17 BRCA1 CCND1 BRCA2 AR AKT1 ESR1
19 craniofacial MP:0005382 10.15 CCND1 AR ERBB2 KRT14 KRT5 TP53
20 liver/biliary system MP:0005370 10.11 AR AKT1 ESR1 KRT8 TP53 PTGS2
21 reproductive system MP:0005389 10.06 CCND1 BRCA2 CDH1 AKT1 BRCA1 AR
22 no phenotypic analysis MP:0003012 9.95 ESR1 PGR KRT5 TP53 PTGS2 EGFR
23 renal/urinary system MP:0005367 9.86 BRCA1 AR ESR1 TP53 PTGS2 CLDN7
24 pigmentation MP:0001186 9.8 BRCA1 AR KRT14 TP53 EGFR CYP19A1
25 respiratory system MP:0005388 9.61 BRCA1 CCND1 AKT1 ESR1 ERBB2 KRT14
26 skeleton MP:0005390 9.4 BRCA1 CCND1 BRCA2 AR AKT1 ESR1

Drugs & Therapeutics for Ductal Carcinoma in Situ

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Nolvadex 18 49 TAMOXIFEN CITRATE AstraZeneca October 1998

Drugs for Ductal Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 50-18-0, 6055-19-2 2907
3
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2 114977-28-5 148124
4
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
5
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
6 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Alkylating Agents Phase 4,Phase 3,Phase 2
10 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2
12 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
13 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
14
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
15
Tamoxifen Approved Phase 3,Phase 2,Phase 1,Not Applicable 10540-29-1 2733526
16
Carboplatin Approved Phase 2, Phase 3,Phase 3 41575-94-4 10339178 498142 38904
17
Progesterone Approved, Vet_approved Phase 3,Phase 2,Not Applicable,Early Phase 1 57-83-0 5994
18
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
19
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
20
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
21
Exemestane Approved, Investigational Phase 3,Phase 2 107868-30-4 60198
22
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
23
Letrozole Approved, Investigational Phase 3,Phase 2,Not Applicable 112809-51-5 3902
24
Leuprolide Approved, Investigational Phase 3 53714-56-0 3911 657181
25
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 33069-62-4 36314
26
Trastuzumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 180288-69-1 9903
27
Pertuzumab Approved Phase 3,Phase 2,Phase 1 145040-37-5, 380610-27-5 2540
28
Olaparib Approved Phase 2, Phase 3 763113-22-0 23725625
29
Metformin Approved Phase 3 657-24-9 14219 4091
30
Pembrolizumab Approved Phase 3,Early Phase 1 1374853-91-4
31
Menthol Approved Phase 3,Not Applicable 2216-51-5 16666
32
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
33
Adenosine Approved, Investigational Phase 3 58-61-7 60961
34
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 77-92-9 311
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
36
leucovorin Approved, Nutraceutical Phase 3 58-05-9 143 6006
37
Lapatinib Approved March 2007, Investigational Phase 3,Phase 2,Not Applicable 231277-92-2, 388082-78-8 208908 9941095
38 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Not Applicable
39 Aromatase Inhibitors Phase 3,Phase 2,Not Applicable
40 Bone Density Conservation Agents Phase 3,Phase 2,Phase 1,Not Applicable
41 Estrogen Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
42 Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1,Not Applicable
43 Estrogens Phase 3,Phase 2,Phase 1,Not Applicable
44 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Hormones Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Selective Estrogen Receptor Modulators Phase 3,Phase 2,Phase 1,Not Applicable
48 Steroid Synthesis Inhibitors Phase 3,Phase 2,Not Applicable
49 Anti-Allergic Agents Phase 3
50 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 240)
# Name Status NCT ID Phase Drugs
1 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
2 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
3 An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer Completed NCT01660542 Phase 4 Neoadjuvant Chemotherapy with Docetaxel
4 Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery Recruiting NCT02627248 Phase 4 Huaier Granule;Epirubicin;Docetaxel;Cyclophosphamide
5 Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator Unknown status NCT00321048 Phase 3
6 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
7 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
8 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3 mometasone furoate
9 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
10 RAPID: Randomized Trial of Accelerated Partial Breast Irradiation Completed NCT00282035 Phase 3
11 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
12 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
13 Study of Docetaxel in Breast Cancer Patients Completed NCT00174707 Phase 3 epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, cyclophosphamide
14 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
15 Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer Completed NCT00374322 Phase 3 lapatinib
16 Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer Completed NCT00038467 Phase 3 Tamoxifen;Exemestane
17 Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane Completed NCT00036270 Phase 3 exemestane (Aromasin);tamoxifen + exemestane
18 BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer Completed NCT00528567 Phase 3 Bevacizumab;Standard adjuvant chemotherapy
19 Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer Completed NCT02980965 Phase 3 letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel;fluorouracil, epirubicin, cyclophosphamide, docetaxel
20 Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women Completed NCT00003906 Phase 3 Raloxifene;Tamoxifen
21 Management of Low-risk DCIS Recruiting NCT02492607 Phase 3
22 CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer Recruiting NCT02918084 Phase 3 Anastrozole or Letrozole or Exemestane;Anastrozole or Letrozole or Exemestane
23 Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer Recruiting NCT03150576 Phase 2, Phase 3 Olaparib;Paclitaxel and Carboplatin
24 Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer Recruiting NCT01905046 Phase 3 metformin hydrochloride
25 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) Recruiting NCT03036488 Phase 3 Carboplatin;Paclitaxel;Doxorubicin;Epirubicin;Cyclophosphamide;Placebo
26 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
27 Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS) Active, not recruiting NCT00907868 Phase 3
28 Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
29 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ Active, not recruiting NCT00072462 Phase 3 tamoxifen citrate;Anastrozole
30 Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
31 APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer Active, not recruiting NCT00402519 Phase 3
32 Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia Active, not recruiting NCT01357772 Phase 3 Tamoxifen;placebo
33 Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients Active, not recruiting NCT02772731 Phase 3
34 A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer Active, not recruiting NCT01358877 Phase 3 5-Fluorouracil;Carboplatin;Cyclophosphamide;Docetaxel;Doxorubicin;Epirubicin;Paclitaxel;Pertuzumab;Placebo;Trastuzumab
35 Oxybutynin Chloride in Managing Hot Flashes Active, not recruiting NCT02961790 Phase 3 Oxybutynin Chloride
36 A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Active, not recruiting NCT01566721 Phase 3 Herceptin
37 Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer Active, not recruiting NCT00878709 Phase 3 neratinib
38 A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Active, not recruiting NCT01966471 Phase 3 Trastuzumab Emtansine;Trastuzumab;Pertuzumab;Paclitaxel;Epirubicin;Doxorubicin;Docetaxel;Cyclophosphamide;5-Fluorouracil
39 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Active, not recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
40 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
41 A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) Active, not recruiting NCT01772472 Phase 3 trastuzumab;trastuzumab emtansine
42 Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer Enrolling by invitation NCT03580395 Phase 2, Phase 3 Apatinib;paclitaxel;cisplatin
43 A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients Not yet recruiting NCT03561740 Phase 3 capecitabine
44 Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS Withdrawn NCT00324714 Phase 3 risedronate sodium
45 Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS) Unknown status NCT00669747 Phase 2 Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
46 Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
47 Dose Optimization for Pulsed-dose-rate (PDR)/High-dose-rate (HDR) Brachytherapy Alone for Early Breast Cancer Unknown status NCT01175694 Phase 2
48 Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland Unknown status NCT01630226 Phase 2 Neoadjuvant Cisplatin Chemotherapy
49 Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors Unknown status NCT02150525 Phase 2
50 Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid

Search NIH Clinical Center for Ductal Carcinoma in Situ

Genetic Tests for Ductal Carcinoma in Situ

Genetic tests related to Ductal Carcinoma in Situ:

# Genetic test Affiliating Genes
1 Ductal Carcinoma in Situ 29

Anatomical Context for Ductal Carcinoma in Situ

MalaCards organs/tissues related to Ductal Carcinoma in Situ:

41
Breast, Lymph Node, Testes, Bone, Skin, Liver, Prostate

Publications for Ductal Carcinoma in Situ

Articles related to Ductal Carcinoma in Situ:

(show top 50) (show all 905)
# Title Authors Year
1
Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. ( 29955142 )
2018
2
The PPARI^ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ. ( 29350308 )
2018
3
Glucocorticoids promote transition of ductal carcinoma in situ to invasive ductal carcinoma by inducing myoepithelial cell apoptosis. ( 29973218 )
2018
4
Oncoplastic breast surgery for the management of ductal carcinoma in situ (DCIS): is it oncologically safe? A retrospective cohort analysis. ( 29759643 )
2018
5
Prediction of Occult Invasive Disease in Ductal Carcinoma in Situ Using Deep Learning Features. ( 29398498 )
2018
6
Magnetic resonance imaging findings of high-grade ductal carcinoma in situ of the male breast: A case report. ( 29977557 )
2018
7
Controversies Regarding the Diagnosis and Management of Ductal Carcinoma In Situ. ( 29428007 )
2018
8
Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database. ( 29383628 )
2018
9
The association between post-diagnosis health behaviors and long-term quality of life in survivors of ductal carcinoma in situ: a population-based longitudinal cohort study. ( 29417425 )
2018
10
Development of a Model to Predict Invasiveness in Ductal Carcinoma In Situ Diagnosed by Percutaneous Biopsy-Original Study and Critical Evaluation of the Literature. ( 29798815 )
2018
11
Treating Second Breast Events After Breast-Conserving Surgery for Ductal Carcinoma in Situ. ( 29632058 )
2018
12
Should patients with ductal carcinoma in situ be treated with adjuvant whole breast radiotherapy after breast conservation surgery? ( 29773535 )
2018
13
Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis. ( 29593431 )
2018
14
Trends and clinicopathological predictors of axillary evaluation in ductal carcinoma in situ patients treated with breast-conserving therapy. ( 29271113 )
2018
15
Patient Experiences and Clinician Views on the Role of Radiation Therapy for Ductal Carcinoma In Situ. ( 29439886 )
2018
16
Role of Preoperative Variables in Reducing the Rate of Occult Invasive Disease for Women Considering Active Surveillance for Ductal Carcinoma In Situ-Reply. ( 29344613 )
2018
17
A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis. ( 29445939 )
2018
18
Hypofractionated volumetric modulated arc therapy in ductal carcinoma in situ: toxicity and cosmetic outcome from a prospective series. ( 29322827 )
2018
19
Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. ( 29394917 )
2018
20
Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ. ( 29730730 )
2018
21
Upstaging to invasive ductal carcinoma after mastectomy for ductal carcinoma in situ: predictive factors and role of sentinel lymph node biopsy. ( 29786772 )
2018
22
Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data. ( 29669162 )
2018
23
Role of Preoperative Variables in Reducing the Rate of Occult Invasive Disease for Women Considering Active Surveillance for Ductal Carcinoma In Situ. ( 29344621 )
2018
24
Factors associated with the increasing trend of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ: Analysis of Surveillance, Epidemiology, and End Results data. ( 29804045 )
2018
25
Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. ( 29398324 )
2018
26
Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery. ( 29709458 )
2018
27
Evaluation of survivin immunoexpression in the differentiation of high- and low-grade breast ductal carcinoma in situ. ( 29694611 )
2018
28
Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women. ( 29207971 )
2017
29
Severe depression more common in patients with ductal carcinoma in situ than early-stage invasive breast cancer patients. ( 28894982 )
2017
30
Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function. ( 28330493 )
2017
31
Effect of radiotherapy after breast-conserving surgery in older patients with early breast cancer and breast ductal carcinoma in situ: a meta-analysis. ( 28415667 )
2017
32
(18)F-fluorodeoxyglucose uptake as predictor for invasion in preoperatively diagnosed breast ductal carcinoma in situ: Significance in cases without mass formation. ( 28781782 )
2017
33
Ductal Carcinoma in situ Detected during Prospective MR Imaging Screening of a Woman with a BRCA2 Mutation: The First Case Report in Japan. ( 28090007 )
2017
34
Patient-reported outcomes in ductal carcinoma in situ: A systematic review. ( 27987454 )
2017
35
Performance characteristics of specimen radiography for margin assessment for ductal carcinoma in situ: a systematic review. ( 28831674 )
2017
36
Impact of Detection Method and Accompanying Ductal Carcinoma in Situ on Prognosis of T1a,bN0 Breast Cancer. ( 28819437 )
2017
37
Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma in situ through activation of TGFI^ signaling. ( 28512126 )
2017
38
Ki-67 Expression as a Factor Predicting Recurrence of Ductal Carcinoma In Situ of the Breast: A Systematic Review and Meta-Analysis. ( 29325859 )
2017
39
Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ. ( 28506312 )
2017
40
Association Between Hospital Financial Distress and Immediate Breast Reconstruction Surgery After Mastectomy Among Women With Ductal Carcinoma In Situ. ( 29214316 )
2017
41
Ductal Carcinoma in Situ: Quantitative Preoperative Breast MR Imaging Features Associated with Recurrence after Treatment. ( 28914599 )
2017
42
Factors influencing local control in patients undergoing breast conservation surgery for ductal carcinoma in situ. ( 27871025 )
2017
43
Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma? ( 28911076 )
2017
44
Trends in the use of implantable accelerated partial breast irradiation for ductal carcinoma in situ: Implications of the recent amendments to the American Society for Radiation Oncology consensus guidelines. ( 28063816 )
2017
45
The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study. ( 29096155 )
2017
46
Comparison of Proliferation Markers Ki67 and Phosphohistone-H3 (pHH3) in Breast Ductal Carcinoma In Situ. ( 28885232 )
2017
47
Radiation Therapy Following Breast Conserving Surgery for Ductal Carcinoma in situ: Yes or No? ( 28862116 )
2017
48
Availability of immunocytochemistry using cocktail antibody targeting p63/cytokeratin14 for the differential diagnosis of fibroadenoma and ductal carcinoma in situ in fine needle aspiration cytology of the breast. ( 28685877 )
2017
49
SOX11 promotes invasive growth and ductal carcinoma in situ progression. ( 28707729 )
2017
50
Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. ( 28338653 )
2017

Variations for Ductal Carcinoma in Situ

Cosmic variations for Ductal Carcinoma in Situ:

9
(show all 44)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6005476 ZFHX3 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2403A>T p.K801N 16:72957743-72957743 7
2 COSM10656 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.742C>T p.R248W 17:7674221-7674221 7
3 COSM43559 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.517G>T p.V173L 17:7675095-7675095 7
4 COSM10701 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.824G>T p.C275F 17:7673796-7673796 7
5 COSM10867 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.797G>A p.G266E 17:7673823-7673823 7
6 COSM44415 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.711G>C p.M237I 17:7674252-7674252 7
7 COSM44737 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.860A>G p.E287G 17:7673760-7673760 7
8 COSM6932 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.733G>A p.G245S 17:7674230-7674230 7
9 COSM10662 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.743G>A p.R248Q 17:7674220-7674220 7
10 COSM10779 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>T p.R273L 17:7673802-7673802 7
11 COSM43714 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.836G>A p.G279E 17:7673784-7673784 7
12 COSM44901 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.532C>G p.H178D 17:7675080-7675080 7
13 COSM10660 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.818G>A p.R273H 17:7673802-7673802 7
14 COSM43814 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.587G>C p.R196P 17:7674944-7674944 7
15 COSM11089 TP53 breast,NS,carcinoma in situ,ductal carcinoma in situ c.584T>C p.I195T 17:7674947-7674947 7
16 COSM6906973 SMARCA4 breast,NS,carcinoma in situ,ductal carcinoma in situ c.1111G>T p.E371* 19:10987917-10987917 7
17 COSM6906974 PPP2R1A breast,NS,carcinoma in situ,ductal carcinoma in situ c.510C>A p.F170L 19:52212692-52212692 7
18 COSM775 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3140A>G p.H1047R 3:179234297-179234297 7
19 COSM12458 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1634A>C p.E545A 3:179218304-179218304 7
20 COSM776 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3140A>T p.H1047L 3:179234297-179234297 7
21 COSM760 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1624G>A p.E542K 3:179218294-179218294 7
22 COSM774 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.3139C>T p.H1047Y 3:179234296-179234296 7
23 COSM763 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1633G>A p.E545K 3:179218303-179218303 7
24 COSM754 PIK3CA breast,NS,carcinoma in situ,ductal carcinoma in situ c.1035T>A p.N345K 3:179203765-179203765 7
25 COSM580 NRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.181C>A p.Q61K 1:114713909-114713909 7
26 COSM565 NRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>C p.G12A 1:114716126-114716126 7
27 COSM6057047 NOTCH1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.7372C>T p.P2458S 9:136496367-136496367 7
28 COSM6005481 MAP2K2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.931G>T p.D311Y 19:4097332-4097332 7
29 COSM521 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>A p.G12D 12:25245350-25245350 7
30 COSM532 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.38G>A p.G13D 12:25245347-25245347 7
31 COSM516 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.34G>T p.G12C 12:25245351-25245351 7
32 COSM520 KRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.35G>T p.G12V 12:25245350-25245350 7
33 COSM1179671 KMT2C breast,NS,carcinoma in situ,ductal carcinoma in situ c.925C>T p.P309S 7:152273792-152273792 7
34 COSM4595028 KMT2C breast,NS,carcinoma in situ,ductal carcinoma in situ c.2681G>A p.R894Q 7:152235905-152235905 7
35 COSM6057048 HRAS breast,NS,carcinoma in situ,ductal carcinoma in situ c.148A>G p.T50A 11:533908-533908 7
36 COSM6906971 H3F3A breast,NS,carcinoma in situ,ductal carcinoma in situ c.218G>A p.R73Q 1:226065745-226065745 7
37 COSM48358 ERBB2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.929C>T p.S310F 17:39711955-39711955 7
38 COSM14060 ERBB2 breast,NS,carcinoma in situ,ductal carcinoma in situ c.2264T>C p.L755S 17:39723967-39723967 7
39 COSM19786 CDH1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.779C>T p.P260L 16:68810288-68810288 7
40 COSM6057049 AKT1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.61A>G p.T21A 14:104780202-104780202 7
41 COSM33765 AKT1 breast,NS,carcinoma in situ,ductal carcinoma in situ c.49G>A p.E17K 14:104780214-104780214 7
42 COSM5174142 breast,NS,carcinoma in situ,ductal carcinoma in situ c.884C>T p.S295F 17:39711955-39711955 7
43 COSM6906972 breast,NS,carcinoma in situ,ductal carcinoma in situ c.1111G>T p.E371* 19:10987917-10987917 7
44 COSM6964823 breast,NS,carcinoma in situ,ductal carcinoma in situ c.659C>T p.T220M 1:39897898-39897898 7

Expression for Ductal Carcinoma in Situ

Search GEO for disease gene expression data for Ductal Carcinoma in Situ.

Pathways for Ductal Carcinoma in Situ

Pathways related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 AKT1 BRCA1 CCND1 CDH1 EGFR ERBB2
2
Show member pathways
13.76 AKT1 BRCA1 BRCA2 CCND1 EGFR ERBB2
3
Show member pathways
13.39 AKT1 CCND1 EGFR ERBB2 MUC1 PTGS2
4
Show member pathways
13 AKT1 BRCA1 CCND1 EGFR ERBB2 PTGS2
5
Show member pathways
12.8 AKT1 AR BRCA2 CCND1 CDH1 EGFR
6
Show member pathways
12.75 AKT1 CDH1 ERBB2 ESR1 PTGS2 TP53
7
Show member pathways
12.73 BRCA1 BRCA2 CCND1 ESR1 TP53
8
Show member pathways
12.58 AKT1 BRCA1 BRCA2 CCND1 CDH1 EGFR
9 12.58 AKT1 AR BRCA2 CCND1 CDH1 EGFR
10
Show member pathways
12.52 AKT1 CCND1 EGFR ERBB2 TP53
11 12.52 BRCA1 CCND1 EGFR ERBB2 PTGS2 TP53
12
Show member pathways
12.46 AKT1 CCND1 CDH1 EGFR ERBB2 MUC1
13
Show member pathways
12.42 AKT1 BRCA1 ESR1 PTGS2
14
Show member pathways
12.33 AKT1 CCND1 EGFR ERBB2 ESR1 PTGS2
15
Show member pathways
12.32 AKT1 BRCA1 BRCA2 CCND1 CDH1 EGFR
16
Show member pathways
12.29 AKT1 BRCA1 CCND1 TP53
17 12.28 AKT1 CCND1 EGFR ERBB2 ESR1 TP53
18
Show member pathways
12.26 BRCA1 CCND1 ESR1 PGR
19 12.19 AKT1 CCND1 EGFR ERBB2 TP53
20
Show member pathways
12.12 AKT1 AR CCND1 EGFR ERBB2
21 12.11 AKT1 CLDN7 EGFR TP53
22
Show member pathways
12.1 AKT1 CCND1 EGFR ERBB2
23
Show member pathways
12.09 CCND1 EGFR ERBB2
24
Show member pathways
12.08 AKT1 EGFR ERBB2 TP53
25 12.06 CCND1 EGFR PTGS2 TP53
26 12.06 AKT1 CCND1 CDH1 EGFR PTGS2 TP53
27
Show member pathways
12.03 AKT1 CCND1 CDH1 PTGS2 TP53
28 12.03 AKT1 CCND1 ESR1 TP53
29 12.02 AKT1 CCND1 ERBB2 TP53
30 12 AKT1 CCND1 EGFR TP53
31 12 AKT1 CCND1 MUC1 PTGS2 TP53
32
Show member pathways
11.98 AKT1 EGFR TP53
33
Show member pathways
11.98 EGFR ERBB2 ESR1 PGR
34 11.91 AKT1 CCND1 PTGS2 TP53
35 11.84 AKT1 KRT14 KRT5 TP53
36
Show member pathways
11.83 BRCA1 BRCA2 TP53
37 11.83 AKT1 AR BRCA1 CCND1 EGFR
38 11.8 AR CCND1 CDH1
39 11.79 AKT1 AR ESR1
40 11.78 AKT1 BRCA1 ERBB2 TP53
41 11.76 CDH1 EGFR ERBB2
42
Show member pathways
11.74 CCND1 EGFR ESR1
43 11.73 AKT1 EGFR ERBB2
44 11.73 AKT1 BRCA1 ERBB2 TP53
45 11.72 AKT1 CCND1 EGFR ESR1
46 11.71 AKT1 EGFR ERBB2 TP53
47 11.67 BRCA1 CCND1 ERBB2 S100A7
48 11.67 CCND1 CDH1 EGFR ERBB2 TP53
49 11.63 AKT1 AR BRCA1 CCND1
50 11.62 AKT1 CCND1 TP53

GO Terms for Ductal Carcinoma in Situ

Cellular components related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.89 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
2 nuclear chromatin GO:0000790 9.56 AR ESR1 MUC1 TP53
3 protein-containing complex GO:0032991 9.23 AKT1 AR BRCA1 BRCA2 EGFR ESR1
4 nucleus GO:0005634 10.06 AKT1 AR BRCA1 BRCA2 CCND1 EGFR

Biological processes related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.98 BRCA1 BRCA2 EGFR PTGS2
2 cytokine-mediated signaling pathway GO:0019221 9.95 AKT1 CCND1 MUC1 PTGS2 TP53
3 transcription initiation from RNA polymerase II promoter GO:0006367 9.9 AR CCND1 ESR1 PGR
4 positive regulation of protein phosphorylation GO:0001934 9.89 AKT1 CCND1 EGFR ERBB2
5 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.85 AKT1 EGFR PTGS2
6 positive regulation of gene expression GO:0010628 9.85 AKT1 AR BRCA1 ERBB2 PIP TP53
7 positive regulation of cell growth GO:0030307 9.83 AKT1 EGFR ERBB2
8 cellular response to mechanical stimulus GO:0071260 9.83 AKT1 EGFR PTGS2
9 response to estrogen GO:0043627 9.81 BRCA1 CCND1 ESR1
10 steroid hormone mediated signaling pathway GO:0043401 9.81 AR ESR1 PGR
11 cell proliferation GO:0008283 9.8 AKT1 AR BRCA2 EGFR ERBB2 TP53
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.79 AKT1 EGFR PTGS2
13 cellular response to growth factor stimulus GO:0071363 9.78 AKT1 EGFR ERBB2
14 epidermis development GO:0008544 9.78 EGFR KRT14 KRT5 S100A7
15 response to estradiol GO:0032355 9.76 CCND1 EGFR ESR1 PTGS2
16 positive regulation of transcription, DNA-templated GO:0045893 9.76 AKT1 AR BRCA1 BRCA2 CDH1 EGFR
17 cellular response to epidermal growth factor stimulus GO:0071364 9.75 AKT1 EGFR ERBB2
18 response to organic substance GO:0010033 9.73 AKT1 CCND1 CDH1 PTGS2
19 positive regulation of vasoconstriction GO:0045907 9.69 AKT1 EGFR PTGS2
20 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.67 ESR1 TP53
21 hemidesmosome assembly GO:0031581 9.67 KRT14 KRT5
22 Leydig cell differentiation GO:0033327 9.66 AR CCND1
23 positive regulation of transcription by RNA polymerase III GO:0045945 9.66 AR ERBB2
24 mitotic G1 DNA damage checkpoint GO:0031571 9.65 CCND1 TP53
25 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.63 AKT1 EGFR
26 prostate gland growth GO:0060736 9.62 AR CYP19A1
27 cellular response to indole-3-methanol GO:0071681 9.58 BRCA1 CDH1
28 response to X-ray GO:0010165 9.58 BRCA2 CCND1 TP53
29 chordate embryonic development GO:0043009 9.57 BRCA1 BRCA2
30 morphogenesis of an epithelial fold GO:0060571 9.56 AR EGFR
31 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.49 AR PGR
32 mammary gland alveolus development GO:0060749 9.43 AR CCND1 ESR1
33 response to UV-A GO:0070141 9.13 AKT1 CCND1 EGFR
34 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.92 BRCA1 BRCA2 MUC1 TP53
35 positive regulation of transcription by RNA polymerase II GO:0045944 10.16 AKT1 AR BRCA1 EGFR ESR1 PGR
36 cellular response to DNA damage stimulus GO:0006974 10.04 AKT1 BRCA1 BRCA2 CCND1 TP53
37 negative regulation of apoptotic process GO:0043066 10.01 AKT1 CLDN7 EGFR ERBB2 PTGS2 TP53
38 positive regulation of cell proliferation GO:0008284 10 AKT1 AR CCND1 CLDN7 EGFR PTGS2

Molecular functions related to Ductal Carcinoma in Situ according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.88 AKT1 CCND1 EGFR ESR1 TP53
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.83 AR ESR1 MUC1 PGR TP53
3 identical protein binding GO:0042802 9.81 AKT1 BRCA2 CDH1 CLDN7 EGFR ERBB2
4 beta-catenin binding GO:0008013 9.72 AR CDH1 ESR1
5 ATPase binding GO:0051117 9.71 AR ESR1 PGR
6 protein phosphatase binding GO:0019903 9.67 EGFR ERBB2 TP53
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.63 EGFR ERBB2 ESR1
8 steroid hormone receptor activity GO:0003707 9.58 AR ESR1 PGR
9 nuclear receptor activity GO:0004879 9.54 AR ESR1 PGR
10 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.51 EGFR ERBB2
11 steroid binding GO:0005496 9.5 AR ESR1 PGR
12 enzyme binding GO:0019899 9.28 AKT1 AR BRCA1 CCND1 EGFR ESR1
13 nitric-oxide synthase regulator activity GO:0030235 9.13 AKT1 EGFR ESR1
14 protein binding GO:0005515 10.23 AKT1 AR BRCA1 BRCA2 CCND1 CDH1
15 zinc ion binding GO:0008270 10 AR BRCA1 ESR1 PGR S100A7 TP53

Sources for Ductal Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....